Symbols / MLAB Stock $97.96 +1.09% Mesa Laboratories, Inc.

Technology • Scientific & Technical Instruments • United States • NMS
MLAB (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Technology
Industry Scientific & Technical Instruments
CEO Dr. Siddhartha Chandrakant Kadia B.E., M.…
Exch · Country NMS · United States
Market Cap 541.21M
Enterprise Value 680.76M
Income 3.73M
Sales 247.54M
FCF (ttm) 36.83M
Book/sh 33.79
Cash/sh 5.51
Employees 730
Insider 10d —
IPO Feb 29, 1984
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 98.46%
P/E 150.71
Forward P/E 18.17
PEG —
P/S 2.19
P/B 2.90
P/C —
EV/EBITDA 16.11
EV/Sales 2.75
Quick Ratio 1.30
Current Ratio 1.94
Debt/Eq 91.07
LT Debt/Eq —
EPS (ttm) 0.65
EPS next Y 5.39
EPS Growth —
Revenue Growth 3.60%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-28
Earnings (prior) 2026-02-03
ROA 2.47%
ROE 2.18%
ROIC —
Gross Margin 62.40%
Oper. Margin 12.25%
Profit Margin 1.51%
Shs Outstand 5.52M
Shs Float 4.94M
Insider Own 5.44%
Instit Own 96.61%
Short Float 5.23%
Short Ratio 1.84
Short Interest 198.40K
52W High 131.20
vs 52W High -25.34%
52W Low 55.45
vs 52W Low 76.66%
Beta 0.89
Impl. Vol. —
Rel Volume 1.31
Avg Volume 109.56K
Volume 143.50K
Target (mean) $104.50
Tgt Median $104.50
Tgt Low $94.00
Tgt High $115.00
# Analysts 2
Recom None
Prev Close $96.90
Price $97.96
Change 1.09%
About

Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides testing and laboratory services to the dental and pharmaceutical industries. Its Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for inherited genetic disease testing, pharmacogenetics, oncology testing, infectious disease testing, doping and toxicology testing, and other differentiated applications for use in research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; PurePep Chorus and Symphony instruments for peptide synthesis; and PurePep EasyClean products for purifying peptides. Its Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as environmental and process monitoring, dialysis, gas flow, air quality, and torque testing in medical device and pharmaceutical manufacturing, laboratory, and hospital environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems under DialyGuard, ViewPoint, DataTrace, DryCal, and BGI brands. Mesa Laboratories, Inc. was incorporated in 1982 and is headquartered in Lakewood, Colorado.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$104.50
Mean price target
2. Current target
$97.96
Latest analyst target
3. DCF / Fair value
$120.01
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$97.96
Low
$94.00
High
$115.00
Mean
$104.50

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-02-04 main Wells Fargo Equal-Weight → Equal-Weight $94
2025-12-15 main Wells Fargo Equal-Weight → Equal-Weight $83
2025-08-08 up Wells Fargo Underweight → Equal-Weight $67
2025-05-30 main Wells Fargo Underweight → Underweight $100
2024-10-01 main Evercore ISI Group Outperform → Outperform $160
2024-08-27 init Wells Fargo — → Underweight $120
2024-08-06 main Evercore ISI Group Outperform → Outperform $120
2024-07-02 main Evercore ISI Group Outperform → Outperform $106
2024-04-04 main Evercore ISI Group Outperform → Outperform $130
2024-01-04 up Evercore ISI Group In-Line → Outperform $125
2021-01-04 down Evercore ISI Group Outperform → In-Line $300
2020-11-10 init Keybanc — → Sector Weight —
2020-10-02 init JP Morgan — → Neutral $260
2019-12-04 init Jefferies — → Buy $275
2019-08-26 init Evercore ISI Group — → Outperform $250
2016-06-10 down Sidoti & Co. Buy → Neutral —
2016-02-10 init Janney Montgomery Scott — → Buy —
News
RSS: Latest MLAB news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-10 TRIPENY R TONY Director — 1,315 $76.00 $99,940
2026-03-10 CAPONE MARK CHRISTOPHER Director — 1,301 $76.35 $99,331
2026-03-10 LADIWALA SHIRAZ SHABANALI Director — 3,500 $72.23 $252,805
2025-12-02 SULLIVAN JOHN JAMES Director — 2,000 $0.00 $0
2025-10-27 OWENS GARY M Chief Executive Officer — 11,558 — —
2025-08-15 SULLIVAN JOHN JAMES Director — 1,404 — —
2025-08-15 TRIPENY R TONY Director — 1,404 — —
2025-08-15 CAPONE MARK CHRISTOPHER Director — 1,404 — —
2025-08-15 HALL SHANNON Director — 1,404 — —
2025-08-15 LADIWALA SHIRAZ SHABANALI Director — 1,949 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Total Revenue
240.98
+11.47%
216.19
-1.32%
219.08
+18.85%
184.34
Operating Revenue
240.98
+11.47%
216.19
-1.32%
219.08
+18.85%
184.34
Cost Of Revenue
90.11
+8.65%
82.94
-2.87%
85.39
+13.48%
75.25
Reconciled Cost Of Revenue
90.11
+8.65%
82.94
-2.87%
85.39
+13.48%
75.25
Gross Profit
150.87
+13.22%
133.25
-0.33%
133.69
+22.55%
109.09
Operating Expense
134.53
+2.86%
130.79
+0.32%
130.37
+24.89%
104.39
Research And Development
19.52
+1.13%
19.30
-5.81%
20.49
+29.95%
15.77
Selling General And Administration
115.02
+3.16%
111.49
+1.46%
109.88
+23.99%
88.62
Selling And Marketing Expense
41.68
+7.92%
38.62
+3.17%
37.44
+32.25%
28.31
General And Administrative Expense
73.33
+0.64%
72.87
+0.58%
72.44
+20.12%
60.31
Other Gand A
73.33
+0.64%
72.87
+0.58%
72.44
+20.12%
60.31
Total Expenses
224.64
+5.11%
213.73
-0.94%
215.76
+20.11%
179.63
Operating Income
16.34
+564.61%
2.46
-25.96%
3.32
-29.39%
4.70
Total Operating Income As Reported
16.34
+106.00%
-272.07
-8295.03%
3.32
-29.39%
4.70
EBITDA
42.35
+117.76%
-238.38
-735.42%
37.52
+15.33%
32.53
Normalized EBITDA
39.46
+9.14%
36.16
-3.62%
37.52
+15.33%
32.53
Reconciled Depreciation
24.53
-22.32%
31.57
-4.71%
33.13
+32.18%
25.07
EBIT
17.82
+106.60%
-269.95
-6261.86%
4.38
-41.27%
7.46
Total Unusual Items
2.89
+101.05%
-274.53
0.00
0.00
Total Unusual Items Excluding Goodwill
2.89
+101.05%
-274.53
0.00
0.00
Special Income Charges
2.89
+101.05%
-274.53
0.00
0.00
Other Special Charges
-2.89
—
—
—
Impairment Of Capital Assets
0.00
-100.00%
274.53
0.00
0.00
Net Income
-1.97
+99.22%
-254.25
-27438.28%
0.93
-50.29%
1.87
Pretax Income
5.96
+102.16%
-275.65
-70760.67%
-0.39
-110.88%
3.57
Net Non Operating Interest Income Expense
-11.86
-108.16%
-5.70
-19.43%
-4.77
-22.78%
-3.88
Interest Expense Non Operating
11.86
+108.16%
5.70
+19.43%
4.77
+22.78%
3.88
Net Interest Income
-11.86
-108.16%
-5.70
-19.43%
-4.77
-22.78%
-3.88
Interest Expense
11.86
+108.16%
5.70
+19.43%
4.77
+22.78%
3.88
Other Income Expense
1.48
+100.54%
-272.41
-25774.74%
1.06
-61.52%
2.76
Other Non Operating Income Expenses
-1.40
-166.05%
2.12
+100.19%
1.06
-61.52%
2.76
Tax Provision
7.93
+137.08%
-21.40
-1522.59%
-1.32
-177.45%
1.70
Tax Rate For Calcs
0.00
+170.47%
0.00
-63.03%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
0.61
+102.84%
-21.32
0.00
0.00
Net Income Including Noncontrolling Interests
-1.97
+99.22%
-254.25
-27438.28%
0.93
-50.29%
1.87
Net Income From Continuing Operation Net Minority Interest
-1.97
+99.22%
-254.25
-27438.28%
0.93
-50.29%
1.87
Net Income From Continuing And Discontinued Operation
-1.97
+99.22%
-254.25
-27438.28%
0.93
-50.29%
1.87
Net Income Continuous Operations
-1.97
+99.22%
-254.25
-27438.28%
0.93
-50.29%
1.87
Normalized Income
-4.25
-313.71%
-1.03
-210.58%
0.93
-50.29%
1.87
Net Income Common Stockholders
-1.97
+99.22%
-254.25
-27438.28%
0.93
-50.29%
1.87
Diluted EPS
-0.36
+99.24%
-47.20
-27864.71%
0.17
-51.43%
0.35
Basic EPS
-0.36
+99.24%
-47.20
-27864.71%
0.17
-52.78%
0.36
Basic Average Shares
5.42
+0.65%
5.39
+1.22%
5.32
+2.09%
5.21
Diluted Average Shares
5.42
+0.65%
5.39
+0.47%
5.36
+0.49%
5.33
Diluted NI Availto Com Stockholders
-1.97
+99.22%
-254.25
-27438.28%
0.93
-50.29%
1.87
Line Item Trend 2024-03-31
Total Assets
446.80
Current Assets
109.35
Cash Cash Equivalents And Short Term Investments
28.21
Cash And Cash Equivalents
28.21
Receivables
39.05
Accounts Receivable
39.05
Gross Accounts Receivable
40.38
Allowance For Doubtful Accounts Receivable
-1.32
Inventory
32.67
Raw Materials
18.34
Work In Process
1.26
Finished Goods
13.08
Prepaid Assets
6.07
Other Current Assets
3.34
Total Non Current Assets
337.44
Net PPE
31.77
Gross PPE
54.28
Accumulated Depreciation
-22.52
Properties
0.00
Land And Improvements
0.89
Buildings And Improvements
23.48
Machinery Furniture Equipment
3.61
Construction In Progress
1.38
Other Properties
24.92
Goodwill And Other Intangible Assets
293.85
Goodwill
180.10
Other Intangible Assets
113.75
Non Current Deferred Assets
1.29
Non Current Deferred Taxes Assets
1.29
Other Non Current Assets
10.54
Total Liabilities Net Minority Interest
301.40
Current Liabilities
44.31
Payables And Accrued Expenses
25.85
Payables
23.15
Accounts Payable
6.04
Other Payable
7.98
Current Accrued Expenses
2.70
Total Tax Payable
9.13
Income Tax Payable
1.61
Current Debt And Capital Lease Obligation
2.99
Current Debt
—
Other Current Borrowings
—
Current Capital Lease Obligation
2.99
Current Deferred Liabilities
15.48
Current Deferred Revenue
15.48
Total Non Current Liabilities Net Minority Interest
257.09
Long Term Debt And Capital Lease Obligation
221.70
Long Term Debt
221.70
Non Current Deferred Liabilities
19.78
Non Current Deferred Taxes Liabilities
19.78
Other Non Current Liabilities
15.61
Stockholders Equity
145.39
Common Stock Equity
145.39
Capital Stock
343.64
Common Stock
343.64
Share Issued
5.39
Ordinary Shares Number
5.39
Treasury Shares Number
0.00
Retained Earnings
-183.49
Gains Losses Not Affecting Retained Earnings
-14.76
Other Equity Adjustments
-14.76
Total Equity Gross Minority Interest
145.39
Total Capitalization
367.09
Working Capital
65.04
Invested Capital
367.09
Total Debt
224.68
Net Debt
193.48
Capital Lease Obligations
2.99
Net Tangible Assets
-148.46
Tangible Book Value
-148.46
Line Item Trend 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Operating Cash Flow
46.81
+6.06%
44.13
+57.71%
27.98
-28.66%
39.22
Cash Flow From Continuing Operating Activities
46.81
+6.06%
44.13
+57.71%
27.98
-28.66%
39.22
Net Income From Continuing Operations
-1.97
+99.22%
-254.25
-27438.28%
0.93
-50.29%
1.87
Depreciation Amortization Depletion
24.53
-22.32%
31.57
-4.71%
33.13
+32.18%
25.07
Depreciation
5.38
+27.14%
4.23
-1.85%
4.31
+32.22%
3.26
Amortization Cash Flow
19.14
-29.98%
27.34
-5.14%
28.82
+32.17%
21.81
Depreciation And Amortization
24.53
-22.32%
31.57
-4.71%
33.13
+32.18%
25.07
Amortization Of Intangibles
19.14
-29.98%
27.34
-5.14%
28.82
+32.17%
21.81
Other Non Cash Items
7.17
+157.47%
2.78
+40.11%
1.99
-75.03%
7.96
Stock Based Compensation
13.14
+10.10%
11.94
-4.80%
12.54
+10.07%
11.39
Asset Impairment Charge
0.00
-100.00%
274.53
0.00
0.00
Deferred Tax
-0.07
+99.75%
-28.42
-713.42%
-3.49
-2829.69%
0.13
Deferred Income Tax
-0.07
+99.75%
-28.42
-713.42%
-3.49
-2829.69%
0.13
Operating Gains Losses
-2.89
—
—
—
Change In Working Capital
6.90
+15.59%
5.97
+134.91%
-17.11
-137.93%
-7.19
Change In Receivables
-2.92
-159.21%
4.94
+332.91%
-2.12
+68.59%
-6.75
Changes In Account Receivables
-2.92
-159.21%
4.94
+332.91%
-2.12
+68.59%
-6.75
Change In Inventory
1.15
-55.01%
2.56
+125.17%
-10.18
-874.35%
-1.04
Change In Prepaid Assets
0.50
+136.02%
0.21
+141.37%
-0.51
+85.86%
-3.61
Change In Payables And Accrued Expense
9.12
+783.87%
-1.33
+72.82%
-4.91
-401.85%
1.62
Change In Accrued Expense
9.50
+868.93%
-1.24
+63.21%
-3.36
-1417.65%
0.26
Change In Payable
-0.39
-300.00%
-0.10
+93.72%
-1.54
-212.77%
1.37
Change In Account Payable
-0.39
-300.00%
-0.10
+93.72%
-1.54
-212.77%
1.37
Change In Other Working Capital
-0.94
-129.90%
-0.41
-167.33%
0.61
-76.57%
2.59
Investing Cash Flow
-4.50
+94.47%
-81.31
-756.39%
-9.49
+96.89%
-305.23
Cash Flow From Continuing Investing Activities
-4.50
+94.47%
-81.31
-756.39%
-9.49
+96.89%
-305.23
Net PPE Purchase And Sale
-4.25
-65.52%
-2.57
+43.51%
-4.54
-2.53%
-4.43
Purchase Of PPE
-4.25
-65.52%
-2.57
+43.51%
-4.54
-2.53%
-4.43
Capital Expenditure
-4.50
-75.26%
-2.57
+43.51%
-4.54
-2.53%
-4.43
Net Business Purchase And Sale
0.00
+100.00%
-78.74
-1490.69%
-4.95
+98.35%
-300.79
Purchase Of Business
0.00
+100.00%
-78.74
-1490.69%
-4.95
+98.35%
-300.79
Net Intangibles Purchase And Sale
-0.25
0.00
0.00
—
Purchase Of Intangibles
-0.25
0.00
0.00
—
Financing Cash Flow
-44.51
-235.55%
32.84
+198.52%
-33.33
-163.39%
52.58
Cash Flow From Continuing Financing Activities
-44.51
-235.55%
32.84
+198.52%
-33.33
-163.39%
52.58
Net Issuance Payments Of Debt
-42.35
-212.92%
37.50
+204.17%
-36.00
-173.47%
49.00
Issuance Of Debt
73.47
+3.47%
71.00
0.00
-100.00%
70.00
Repayment Of Debt
-115.81
-245.70%
-33.50
+6.94%
-36.00
-71.43%
-21.00
Long Term Debt Issuance
73.47
+3.47%
71.00
0.00
-100.00%
70.00
Long Term Debt Payments
-115.81
-245.70%
-33.50
+6.94%
-36.00
-71.43%
-21.00
Net Long Term Debt Issuance
-42.35
-212.92%
37.50
+204.17%
-36.00
-173.47%
49.00
Net Common Stock Issuance
—
—
0.00
0.00
Common Stock Dividend Paid
-3.47
-0.61%
-3.45
-1.20%
-3.41
-2.01%
-3.34
Cash Dividends Paid
-3.47
-0.61%
-3.45
-1.20%
-3.41
-2.01%
-3.34
Proceeds From Stock Option Exercised
2.64
+638.55%
0.36
-94.88%
7.00
-12.83%
8.03
Net Other Financing Charges
-1.34
+14.98%
-1.57
-71.38%
-0.92
+17.36%
-1.11
Changes In Cash
-2.20
+49.27%
-4.34
+70.77%
-14.84
+93.05%
-213.43
Effect Of Exchange Rate Changes
1.31
+464.07%
-0.36
+77.52%
-1.60
-46.11%
-1.09
Beginning Cash Position
28.21
-14.27%
32.91
-33.31%
49.35
-81.30%
263.87
End Cash Position
27.32
-3.17%
28.21
-14.27%
32.91
-33.31%
49.35
Free Cash Flow
42.31
+1.79%
41.57
+77.34%
23.44
-32.63%
34.79
Interest Paid Supplemental Data
11.08
+138.32%
4.65
+33.37%
3.48
+26.18%
2.76
Income Tax Paid Supplemental Data
5.73
+24.83%
4.59
+238.57%
1.36
-55.51%
3.05
Common Stock Issuance
—
—
0.00
0.00
Issuance Of Capital Stock
—
—
0.00
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category